Print this page

Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial.

We will evaluate the online tool our team created under protocol (#Pro2013003029) called Empowered Survivor (ES) against a free online self-management intervention developed for cancer survivors by the National Cancer Institute and the American Cancer Society called Springboard Beyond Cancer.82 600 patients who have completed treatment between one and three years ago and are currently cancer-free will be recruited via the New Jersey State Cancer Registry or the Cancer Registry of Greater California and randomly assigned to ES or Springboard Beyond Cancer. Participants will complete measures at baseline, 2, and 6-months post-baseline. We will also complete a process evaluation of ES.

Objectives
Aim 1: To evaluate the impact of ES versus Springboard Beyond Cancer on the primary outcomes of self-efficacy in managing care, preparedness for managing survivorship, and head and neck specific QOL.

Aim 2: To evaluate mediators (planning, information needs, support needs, activation, and fear of recurrence) and moderators (age, race/ethnicity, sex, HPV status, baseline self-efficacy and preparedness) of ES s impact on self-efficacy in managing care, preparedness, and head and neck specific QOL.

Aim 3: To evaluate the impact of ES versus Springboard Beyond Cancer on the secondary outcomes of engagement in oral self-exams and head and neck mobility exercises.

Exploratory Aim: To conduct a process evaluation of ES to inform future implementation.

Protocol Number: 132004
Phase: Phase III
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Principal Investigator: Sharon Manne PhD
Scope: National
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria ►

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.